EA202190686A1 - 5-7-членные гетероциклические амиды в качестве ингибиторов jak - Google Patents

5-7-членные гетероциклические амиды в качестве ингибиторов jak

Info

Publication number
EA202190686A1
EA202190686A1 EA202190686A EA202190686A EA202190686A1 EA 202190686 A1 EA202190686 A1 EA 202190686A1 EA 202190686 A EA202190686 A EA 202190686A EA 202190686 A EA202190686 A EA 202190686A EA 202190686 A1 EA202190686 A1 EA 202190686A1
Authority
EA
Eurasian Patent Office
Prior art keywords
member heterocyclic
jak inhibitors
heterocyclic amides
compounds
amides
Prior art date
Application number
EA202190686A
Other languages
English (en)
Russian (ru)
Inventor
Дэниэл Д. Лонг
Камерон Смит
Корбин Томпсон
Original Assignee
ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи filed Critical ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи
Publication of EA202190686A1 publication Critical patent/EA202190686A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA202190686A 2018-09-04 2019-09-03 5-7-членные гетероциклические амиды в качестве ингибиторов jak EA202190686A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726583P 2018-09-04 2018-09-04
PCT/US2019/049342 WO2020051139A1 (en) 2018-09-04 2019-09-03 5 to 7 membered heterocyclic amides as jak inhibitors

Publications (1)

Publication Number Publication Date
EA202190686A1 true EA202190686A1 (ru) 2021-07-23

Family

ID=68051893

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190686A EA202190686A1 (ru) 2018-09-04 2019-09-03 5-7-членные гетероциклические амиды в качестве ингибиторов jak

Country Status (20)

Country Link
US (2) US10836763B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837010B1 (cg-RX-API-DMAC7.html)
JP (1) JP7383696B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210056380A (cg-RX-API-DMAC7.html)
CN (1) CN112703037B (cg-RX-API-DMAC7.html)
AR (1) AR116114A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019335200A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021004063A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021000515A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021002976A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190686A1 (cg-RX-API-DMAC7.html)
ES (1) ES2955717T3 (cg-RX-API-DMAC7.html)
IL (1) IL281150B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002484A (cg-RX-API-DMAC7.html)
PH (1) PH12021550324A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101751XA (cg-RX-API-DMAC7.html)
TW (1) TWI793365B (cg-RX-API-DMAC7.html)
UA (1) UA127328C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020051139A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100990B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3161899A4 (en) 2014-06-30 2017-12-27 Black & Decker Inc. Battery pack for a cordless power tools
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
TWI754019B (zh) 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
BR112021004063A2 (pt) * 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
KR20220149585A (ko) 2020-03-02 2022-11-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 화합물의 결정성 수화물
WO2022081872A1 (en) * 2020-10-16 2022-04-21 Gb008, Inc. Janus kinase inhibitors
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN118401508A (zh) * 2021-12-17 2024-07-26 株式会社大熊制药 (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形
AU2025221563A1 (en) * 2024-02-14 2026-07-09 Almirall, S.A. Stat6 inhibitors and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
EP3831830A1 (en) * 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
DK3712152T3 (da) * 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
US10906888B2 (en) * 2016-07-14 2021-02-02 Pfizer Inc. Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
TWI754019B (zh) * 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
EP3619208B1 (en) 2017-05-01 2023-06-07 Theravance Biopharma R&D IP, LLC Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
BR112021004063A2 (pt) * 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
KR102873783B1 (ko) 2019-02-25 2025-10-21 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 Jak 억제제 화합물 및 그 사용
UA130579C2 (uk) 2019-03-05 2026-03-25 Інсайт Корпорейшн Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途

Also Published As

Publication number Publication date
US20200071325A1 (en) 2020-03-05
KR20210056380A (ko) 2021-05-18
ES2955717T3 (es) 2023-12-05
JP2021535174A (ja) 2021-12-16
CN112703037A (zh) 2021-04-23
IL281150B2 (en) 2024-03-01
AR116114A1 (es) 2021-03-31
IL281150B1 (en) 2023-11-01
US10836763B2 (en) 2020-11-17
SG11202101751XA (en) 2021-03-30
TW202024075A (zh) 2020-07-01
ZA202100990B (en) 2024-09-25
CO2021002976A2 (es) 2021-05-31
EP3837010B1 (en) 2023-07-05
US20210024517A1 (en) 2021-01-28
US11713315B2 (en) 2023-08-01
CL2021000515A1 (es) 2021-07-23
MX2021002484A (es) 2021-05-12
PH12021550324A1 (en) 2021-10-04
AU2019335200A1 (en) 2021-03-11
JP7383696B2 (ja) 2023-11-20
EP3837010C0 (en) 2023-07-05
BR112021004063A2 (pt) 2021-05-25
CN112703037B (zh) 2023-10-20
WO2020051139A1 (en) 2020-03-12
IL281150A (en) 2021-04-29
TWI793365B (zh) 2023-02-21
EP3837010A1 (en) 2021-06-23
UA127328C2 (uk) 2023-07-19

Similar Documents

Publication Publication Date Title
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
MX386089B (es) Compuesto heterociclico utilizado como inhibidor de fgfr.
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
JOP20210127A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
EA202090414A1 (ru) Соединения и их применение
EA201692300A1 (ru) Производные карбоксамида
EA202192760A1 (ru) Трициклические соединения
EA202190452A1 (ru) Ингибиторы cdk8/19
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX385475B (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa
EA202190689A1 (ru) Производные хинолина в качестве ингибиторов интегрина альфа4бета7
EA202192382A1 (ru) Соединения, нацеленные на prmt5
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
EA201992005A1 (ru) Арильные, гетероарильные и гетероциклические фармацевтические соединения для лечения медицинских нарушений
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19